Stock Quote Abbott Laboratories Financial News and Trends

Abbott Laboratories is a well-established company with a rich history dating back to 1888. It has evolved significantly over the years, with a focus on developing innovative healthcare solutions.

The company has a diverse portfolio of products, including diagnostics, medical devices, and generic pharmaceuticals. Abbott Laboratories is a multinational corporation with operations in over 130 countries.

Abbott's revenue has been steadily increasing over the years, reaching $43.8 billion in 2020. The company's strong financial performance has enabled it to invest in research and development, driving innovation in the healthcare industry.

You might like: Free Basic Healthcare and Inscrease of Taxes

Abbott Laboratories had a revenue of $41.95 billion in 2024, a 4.59% increase from the previous year's $40.11 billion.

Their earnings in 2024 were $13.40 billion, a significant jump of 135.08% compared to the previous year.

Abbott Laboratories reported fourth-quarter sales of $10.97 billion, which was 7.2% higher than the same period last year, but still fell short of the consensus estimate of $11.01 billion.

Their total worldwide sales for the quarter ended Dec. 31 were $10.97 billion, missing Wall Street estimates of $11.03 billion.

Abbott Laboratories's revenue growth is a notable aspect of their financial performance.

Here's a summary of their revenue and earnings over the past year:

Abbott Laboratories has been making headlines recently with some exciting developments. Abbott Laboratories' stock price has been on the rise due to its impressive financial performance.

The company reported a 10% increase in revenue in the first quarter of the year, reaching $10.3 billion. This is a testament to its strong market position and ability to innovate.

Abbott's medical device segment saw a 12% growth, driven by the success of its FreeStyle Libre glucose monitoring system. This system has been a game-changer for people with diabetes, providing accurate and convenient glucose readings.

Abbott's stock price has also been boosted by its acquisition of St. Jude Medical, a leading manufacturer of cardiovascular devices. This deal has expanded Abbott's portfolio and increased its presence in the medical device market.

Abbott's commitment to innovation and R&D has paid off, with the company investing $1.5 billion in research and development last year. This investment has led to the development of new products and technologies that are changing the face of healthcare.

You might enjoy: Omega Healthcare Investors Stock

Abbott is a global healthcare company that has been around for over 135 years. It was founded in 1888 by Dr. Wallace Abbott in Chicago, Illinois.

The company's name is derived from its founder's name, Dr. Wallace Abbott.

Abbott is headquartered in Illinois, USA, and has operations in over 130 countries worldwide. Its products are sold in more than 160 countries.

Abbott has a diverse portfolio of products, including medical devices, diagnostics, and nutritionals. Its medical devices include heart pumps, pacemakers, and stents.

The company has a strong research and development focus, with a pipeline of innovative products and technologies.

Abbott Laboratories reported fourth-quarter sales of $10.97 billion, which is a 7.2% increase year over year, but missed the consensus of $11.01 billion.

Analysts are optimistic about Abbott stock, with an average rating of "Buy" from 17 analysts and a 12-month stock price forecast of $131.41, representing a 2.37% increase from the latest price.

Abbott forecasts annual profit in line with Wall Street estimates, driven by elevated medtech-related procedures and increased demand for its devices, including glucose monitors.

Abbott Laboratories reported fourth-quarter sales of $10.97 billion, a 7.2% increase year over year, but missed the consensus of $11.01 billion.

The company's stock is trading higher on Thursday, despite missing sales expectations. Analysts are still optimistic about Abbott's future performance.

According to 17 analysts, the average rating for ABT stock is "Buy", with a 12-month stock price forecast of $131.41, a 2.37% increase from the latest price. This suggests a positive outlook for the company's stock.

Abbott forecasted annual profit in line with Wall Street estimates, driven by elevated medtech-related procedures and increased demand for its devices. This bodes well for the company's financial performance.

Crude oil prices edged lower on the market, a slight dip in an otherwise steady trend.

Abbott Laboratories reported weak sales, missing the consensus estimate by a small margin. Their fourth-quarter sales of $10.97 billion only managed to increase by 7.2% year over year, a relatively modest gain.

The decline in crude oil prices is a minor setback, but it's worth keeping an eye on as the market continues to evolve.

In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion.

Abbott Laboratories's sales per share were 24.00 in 2024, a slight decrease from 2023's 22.93.

The company's P/E ratio was 14.75 in 2024, which is significantly lower than 2023's 33.77.

Abbott Laboratories's dividend yield was 1.98% in 2024, which is a relatively stable figure compared to previous years.

Here's a breakdown of Abbott Laboratories's key financial ratios in 2024:

Estimates in USD can be a complex topic, but let's break it down.

The average earnings estimate for Abbott Laboratories in the current quarter ending 03/31/25 is $1.064 USD, based on 20 analysts.

This is up from $0.701 USD in the previous quarter, indicating a possible increase in earnings.

The average revenue estimate for the same quarter is $10,407 USD, also based on 19 analysts.

This is higher than the previous quarter's estimate of $9,964 USD.

Here's a comparison of the average earnings estimates for the next few quarters:

Keep in mind that these estimates are subject to change and should be taken as a general guideline only.

The Dividend Calendar is a crucial tool for investors looking to maximize their returns. Abbott Laboratories has a long history of paying consistent dividends, with the highest payout being $2.24 in 2024.

Abbott Laboratories has increased its dividend payout every year since 2011, with a 3-year dividend growth rate of 12.3%. This growth rate is impressive, and it's no wonder investors are drawn to the company's dividend calendar.

Here's a breakdown of Abbott Laboratories' dividend calendar over the past 20 years:

The table above shows that Abbott Laboratories has consistently paid dividends over the past 20 years, with a significant increase in dividend payout since 2011. This trend is likely to continue, making the company an attractive option for investors seeking stable returns.